Budget impact analysis of the subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in the Big-5 European (E5) countries.
Fiche publication
Date publication
novembre 2022
Journal
BMC health services research
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Yoo HK, Byun HG, Caprioli F, Fumery M, Peyrin-Biroulet L, Sreedhar S, Potter J, Jang M
Lien Pubmed
Résumé
In 2020, the European Medicines Agency approved infliximab subcutaneous (SC) for the treatment of inflammatory bowel disease. This new mode of infliximab administration will reduce outpatient visits and costs of intravenous (IV) administration. This article describes a budget impact analysis of introducing infliximab SC to the Big-5 European (E5) market (Germany, France, Italy, Spain and UK) for 5 years, from the healthcare payer's perspective.
Mots clés
Budget impact, Crohn’s disease, Inflammatory bowel disease, Ulcerative colitis
Référence
BMC Health Serv Res. 2022 11 4;22(1):1319